Gilead Sciences shares soar; analysts lift targets on HIV strength and Yeztugo outlookInvezz • 08/08/25
These Stocks Are Moving Most Today: Trade Desk, Expedia, Pinterest, Twilio, Gilead SciencesBarrons • 08/08/25
Gilead (GILD) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 08/08/25
Will Gilead's Beat-And-Raise Help It Leapfrog Its 50-Day Line Ceiling?Investors Business Daily • 08/07/25
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?Zacks Investment Research • 08/04/25
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challengesWSJ • 08/01/25
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 07/31/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILDPRNewsWire • 07/27/25
Gilead's Newly Approved HIV Prevention Drug Poised To Add Billions To Future SalesBenzinga • 07/25/25